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Abstract
Background: Before furin can act on protein substrates, it must go through an ordered process of activation. Similar to
many other proteinases, furin is synthesized as a zymogen (profurin) which becomes active only after the autocatalytic
removal of its auto-inhibitory prodomain. We hypothesized that to activate profurin its prodomain had to be removed and,
in addition, the emerging enzyme’s N-terminus had to be ejected from the catalytic cleft.
Methodology/Principal Findings: We constructed and analyzed the profurin mutants in which the egress of the emerging
enzyme’s N-terminus from the catalytic cleft was restricted. Mutants were autocatalytically processed at only the primary
cleavage site Arg-Thr-Lys-Arg
107QAsp
108, but not at both the primary and the secondary (Arg-Gly-Val-Thr-Lys-Arg
75QSer
76)
cleavage sites, yielding, as a result, the full-length prodomain and mature furins commencing from the N-terminal Asp108.
These correctly processed furin mutants, however, remained self-inhibited by the constrained N-terminal sequence which
continuously occupied the S9 sub-sites of the catalytic cleft and interfered with the functional activity. Further, using the in
vitro cleavage of the purified prodomain and the analyses of colon carcinoma LoVo cells with the reconstituted expression
of the wild-type and mutant furins, we demonstrated that a three-step autocatalytic processing including the cleavage of
the prodomain at the previously unidentified Arg-Leu-Gln-Arg
89QGlu
90 site, is required for the efficient activation of furin.
Conclusions/Significance: Collectively, our results show the restrictive role of the enzyme’s N-terminal region in the
autocatalytic activation mechanisms. In a conceptual form, our data apply not only to profurin alone but also to a range of
self-activated proteinases.
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Introduction
A variety of proteins, including serine proteinases and
metalloproteinases, growth factors, and adhesion molecules as
well as bacterial and viral pathogens, is initially synthesized as
inactive precursors. Specific processing is required to transform
these proproteins into biologically active proteins [1]. Furin and
related proprotein convertases (PCs) are specialized serine
endoproteinases, which cleave the multibasic motifs R-X-R/K/
X-R to transform proproteins into biologically active proteins and
peptides [2]. Seven furin-family proteases (furin, PACE4, PC1/3,
PC2, PC4, PC5/6 and PC7) have been identified in humans [3].
Ubiquitously expressed furin is the most studied enzyme among all
of the PCs [4,5,6]. Structurally and functionally, furin resembles its
evolutionary precursor, yeast kexin. Furin is synthesized as a pre-
proprotein which contains a signal peptide, a prodomain, a
subtilisin-like catalytic domain, a middle P domain, a cysteine-rich
region, a transmembrane anchor and a cytoplasmic tail. The N-
terminal 81-residue prodomain (residues Gln
27-Arg
107) functions
as a potent auto-inhibitor [7,8]. Furin and other PCs require
proteolytic removal of the inhibitory prodomain to become
proteolytically potent enzymes [2,9].
No natural protein inhibitors of furin are known. The highly
potent synthetic peptidic inhibitor decanoyl-Arg-Val-Lys-Arg-
chloromethylketone (dec-RVKR-cmk) and a1-antitrypsin variant
Portland are used to inhibit furin in cleavage reactions in vitro and
in cell-based tests. The original a1-antitrypsin serpin is the natural
inhibitor of neutrophil elastase [10]. After a natural mutation of
the active site Met358 to Arg the mutant, called a1-antitrypsin
variant Pittsburgh, becomes a potent inhibitor of thrombin [11].
The additional, genetically engineered, mutation at position 355
generates a mutant known as a1-antitrypsin variant Portland (a1-
PDX). As a result of this additional mutation, a1-PDX exhibits a
minimal furin cleavage motif (Arg
355-Ile-Pro-Arg
358-) in its
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PDX inhibits furin by a slow, tight-binding mechanism and,
similar to other serpins, functions as a suicide substrate inhibitor.
Because of these parameters, a1-PDX forms a covalent, SDS- and
heat-stable, complex with functionally active furin [13].
It has been suggested that the activation of the de novo
synthesized furin occurs through a two-step autoproteolytic
mechanism leading to the cleavage of its cognate N-terminal
prodomain. Only a few landmarks of furin activation are known.
The folded furin zymogen initially undergoes an autocatalytic
excision at the primary Arg-Thr-Lys-Arg
107QAsp
108 site [14,15].
This cleavage alone, however, is not sufficient for enzymatic
activation because furin remains inhibited by its non-covalently
associated prodomain [16,17]. After the translocation of furin into
the mildly acidic trans-Golgi network/endoplasmic system, the
primary cleavage is followed by an autocatalytic cleavage at the
secondary Arg-Gly-Val-Thr-Lys-Arg
75QSer
76 site which releases
the prodomain fragments [18,19]. As a result, the prodomain’s
inhibitory function is inactivated and the mature, proteolytically
potent enzyme is generated. These and other studies [20,21] were
focused on the inhibitory prodomain. The functional significance
of the emerging N-terminal mature furin sequence, despite its
obvious role in the autocatalytic activation mechanism, remains
unexplored.
We hypothesized that to render the emerging enzyme
functionally active its N-terminal region had to egress from its
original position in the preformed catalytic cleft of profurin. This
event is in addition to the autocatalytic removal of the inhibitory
prodomain. We also suspect that exhaustive proteolysis of the
liberated prodomain is also required to prevent re-inhibition of the
emerging, activated furin.
To support our hypothesis, we constructed and analyzed
mutant furins with amino acid substitutions and insertions into
the N-terminal region of the emerging enzyme and re-examined
the proteolytic processing of the furin prodomain. Collectively, our
biochemical experiments and in silico modeling determined that an
ejection mechanism is necessary to accomplish the exodus of the
N-terminus from the active site of the emerging enzyme. If this
mechanism is inactivated and the N-terminus is not released from
the catalytic cleft, profurin will be processed but the resulting
enzyme will remain self-inhibited.
Results
Modeling of the activation mechanism
In our modeled profurin structure, the relative position of the
prodomain and the catalytic domain was similar to that reported
for the subtilisin-propeptide complex (Protein Data Bank code
1SCJ). The identified helix sheet interaction of the propeptide with
the catalytic domain is conserved in the subtilisin family [22,23,24]
and also in PCs including furin (Figure 1A). The 101–113
sequence region that spans the primary Arg-Thr-Lys-Arg
107-
QAsp
108 cleavage site was positioned in the active site of profurin
in a manner similar to the dec-RVKR-cmk inhibitor in the 1P8J
crystal structure of murine furin [25,26].
According to the X-ray structure of furin, the position of the N-
terminal Asp108 is ,40 A ˚ away from the catalytic cleft [25]. In
contrast, the primary cleavage site sequence Arg-Thr-Lys-
Arg
107QAsp
108 is located directly in the active site of the latent
profurin. Through its electrostatic interactions with the calcium
ion Asp115 plays a primary role in the active furin conformation




are also multiple hydrophobic interactions of Pro113 with the
neighboring Val213, Phe118 and Trp138 residues. Two addition-
al charge contacts (Glu112-Lys135 and Lys117-Glu362) also play
an important role in the stabilization of the N-terminal 108–117
region. Both the Glu112-Lys135 and Lys117-Glu362 interactions
appear to stabilize the structure of the N-terminal region of the
active furin molecule (Figure 1A).
According to our modeling, the zymogen conformation leading
to self-cleavage provides less favorable contacts for all charged
residues. The electrostatic forces originating from broken ion
bridges provide the energy that would be released as a result of the
Arg-Thr-Lys-Arg
107QAsp
108 site cleavage. This energy burst will
stimulate repositioning of the novel N-terminus (Asp108) and will
lead to the mature furin conformation where Asp108 is 40A ˚ away
from the active site. In the furin zymogen, the egress of the
emerging enzyme’s N-terminal region from the active site follows
the autocatalytic cleavage of the primary cleavage sequence Arg-
Thr-Lys-Arg
107QAsp
108. To accomplish this egress, the unwind-
ing of the 108–117 region structure is necessary. This unwinding
includes a change of the backbone conformation of Lys117, the
abrogation of the electrostatic contact of Asp115 with the calcium
ion and also with other auxiliary electrostatic contacts and the
hydrophobic interactions involving Pro113. It is highly probable
that the autocatalytic cleavage at the Arg-Thr-Lys-Arg
107QAsp
108
site causes Asp115 to become available for electrostatic contact
with the calcium ion and, as a result, reposition the backbone to its
location observed in active furin. To accommodate the ligation of
Asp115 to the calcium ion, the chain reverses direction and ejects
the emerging N-terminus thus liberating the multiple S9 sites of the
active site of the mature, processed, furin. A similar mechanism
was earlier suggested for the maturation of subtilisin BPN’ [27].
According to our modeling, the N-terminal insertions in the
mature furin sequence should result in an extended conformation
in which the primary cleavage site Arg-Thr-Lys-Arg
107QAsp
108
will access the active site without breaking the electrostatic
interactions of Asp115 with the calcium ion (Figure 1B). Following
the cleavage at this primary site, the N-terminal part of the
emerging active furin may become partially mobile, albeit
incapable of achieving the normally occurring 40 A ˚ repositioning,
and, in contrast to wild-type (WT) furin, the N-terminal region
108–117 will continue to occupy the multiple S9 sub-sites of the
active site cavity. In turn, in the K117P mutant the steric
properties of proline will make any significant repositioning of the
N-terminal region nearly impossible, thus making the structure of
the 108–117 region in the activated mature furin similar to that of
profurin.
Recombinant constructs
To support our modeling studies experimentally and to
determine the requirements for the activation of furin, WT and
mutant constructs were designed. To obtain the soluble constructs,
which could be readily isolated from the medium by metal-
chelating chromatography, the human furin sequence was
truncated at Ala574 and the truncation was then linked to a
flexible 7-residue linker followed by a C-terminal His6 tag. To
increase the distance from the N-terminus to the critical Lys117 in
the N-terminal region of furin, we constructed the insertion
mutants. In the insertion mutants, a single Gly residue and the
Gly5 and Gly6 peptide sequences were inserted between positions
Pro113 and Thr114 of the furin sequence (G, G5 and G6 mutants,
respectively). To confirm that the observed effects were not unique
for the Gly-containing sequences, both the positively charged His6
and the negatively charged Asp-Asp-Asp-Asp-Lys sequences were
also inserted between Pro113 and Thr114 (H6 and D4K mutants,
respectively). To determine the role of the hinge motion Lys117,
Activation of Furin
PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5031Figure 1. Structural model of the WT and K117P furins. (A) Stereo view of the WT furin catalytic cleft before (a red ribbon) and after (a blue
ribbon) the cleavage at the primary Arg- Thr-Lys-Arg
107QAsp
108 site. The red curved arrow indicates the motion of the 108–117 sequence from its
position in profurin to its final position in the mature furin enzyme. The open conformation of the mature furin enzyme is stabilized by strong
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the catalytically inert D153N mutant with the substitution of the
essential active site Asp153 (Figure 2A).
The constructs were then expressed in Sf9 cells infected with the
recombinant baculovirus. To determine the efficiency of the
profurin synthesis and the processing and secretion of mature
furins, we used Western blotting of the cell lysate and conditioned
medium aliquots (Figure 2B). Two profurin forms, presumably
preprofurin and profurin, were predominant in the cell lysates
while the processed furin alone was detected in the medium
samples. With the exception of the inert D153N construct, the
levels of the mutants we observed in the cell lysate and medium
samples were comparable with those of the WT construct. Because
the autocatalysis is mandatory for furin processing and secretion,
the inert D153N was efficiently synthesized but inefficiently
processed and secreted. This inefficient processing and secretion
made the purification of the D153N mutant exceedingly difficult.
In addition, the molecular weight of the secreted mutants was
similar to that of the WT construct suggesting that the mutations
did not affect the efficiency of autocatalytic processing and that the
resulting secretory mutants were each capable of prodomain




Isolation and the N-terminal sequence of mutant furins
We purified the mutant constructs to identify their N-terminal
sequence and enzymatic features. In contrast to the inert D153N
mutant, other mutants including the K117P, G, G5, G6, D4K and
H6, were readily isolated from the medium using metal-chelating
chromatography (Figure 2C). Because the properties of the H6-
and G6-furin mutants were very similar, the first will not be
discussed in the text below.
To confirm the conversion of profurin into a correctly
processed, mature furin, the WT, K117P and G6 purified samples
were each subjected to N-terminal microsequencing. Only one N-
terminal peptide sequence (D
108 VYQEP) that corresponded to
mature furin was identified, thus confirming that the WT and the
mutants were processed through an autocatalytic activation





The WT construct exhibited a high proteolytic activity against
the Abz-Arg-Val-Lys-Arg-Gly-Leu-Ala-Tyr(NO2)-Asp-OH
(Figure 3A) and Pyr-Arg-Thr-Lys-Arg-methyl-coumaryl-7-amide
peptide substrates (data not shown). A specific inhibitor of furin
(dec-RVKR-cmk) fully blocked the substrate cleavage by the WT
enzyme. The correctly processed insertion mutants demonstrated
low specific activity against the peptide substrates. A 1000-fold
increase in the levels of the mutants in the cleavage reactions
relative to that of the WT furin was required to detect their
measurable activity.
To corroborate our observations, we tested the ability of the
mutants to specifically cleave anthrax protective antigen-83
(PA83), a target that is highly sensitive to furin proteolysis
[28,29]. PA83 is known to be cleaved by furin at the Arg-Lys-Lys-
Arg
196 site [30,31]. This cleavage converts PA83 into the PA63
functionally active species. Here, PA83 was subjected to
proteolysis by increasing concentrations of the purified furins.
PA83 was efficiently cleaved by the WT furin at an enzyme-
substrate molar ratio as low as 1:10,000 (Figure 3B). A furin
inhibitor dec-RVKR-cmk fully blocked the proteolysis of PA83 by
furin. In contrast to the WT, the insertion mutants demonstrated
very low activity against PA83. According to our tests, the mutants
were 1,000–10,000-fold less potent against PA83 when compared
to the WT enzyme. Based on these results we hypothesized that,
after the prodomain excision the mutants remained self-inhibited
by the N-terminal region of the mature enzyme which still
occupied their active site.
Interactions of furins with a1-PDX
Normally, a1-PDX forms a covalent, SDS- and heat-stable,
complex with functionally active furin [13]. To determine if the
mutants were able to form a complex with a1-PDX, we co-
incubated furins with a1-PDX to generate a1-PDX-furin
complexes. The residual furin activity was inhibited using EDTA
and SDS, and then by heating the samples at 95uC. The reactions
were then analyzed both by SDS-PAGE followed by Coomassie
staining and Western blotting with the MON-148 antibody against
the catalytic domain of furin. Figure 4A shows that a1-PDX
formed a stable complex with the WT furin but not with the
mutants.
We next employed ELISA to analyze, in greater detail, the
ability of furins to form a complex with a1-PDX (Figure 4B). The
wells of a 96-well plate were coated with the purified furins. a1-
PDX tagged with a FLAG tag was then added to the wells. The
levels of the bound a1-PDX were then measured using the FLAG
antibody. We determined that the ability of the mutant constructs
to interact with a1-PDX was comparable with that of the WT
furin. These data suggested that because the multiple S sub-sites
were available in the mutants they were capable of a complex
formation with the a1-PDX serpin but because the abnormally
positioned N-terminal sequence shielded and incapacitated the S9
sub-sites, the inactive were unable to transform the initial
association with the serpin into a kinetically trapped SDS-stable
complex.
Tryptic proteolysis of the furin constructs
To demonstrate that the N-terminal sequence is buried in the
furin’s catalytic cleft of the K117P mutant and exposed in WT
furin, we used mild tryptic digestion. We suggested that the N-
terminal peptides will be efficiently released by trypsin in WT furin
but not in the K117P mutant. In turn, the release of the C-
terminal peptides will be equally efficient in the WT and K117P
constructs. The tryptic digest of the furin constructs followed by
LC-MS/MS and the differential spectral count analysis of the




electrostatic interactions of Asp115 and a calcium ion (a blue sphere), and, in addition, by two salt bridges (Glu112-Lys135 and Lys117-Glu362). (B)
The 26–107 prodomain and the 108–574 catalytic domain-P domain of furin are shown in green and grey, respectively. The modeled structure of the
108–117 sequence in profurin is shown in red while the actual structure of the 108–117 sequence in the mature WT furin enzyme is in blue. Top
panels - In the structure of the WT furin, the 76–107 peptide sequence, which is generated as a result of the secondary cleavage, is shown as an
orange ribbon. The arrows 1 and 2 indicate the primary and the secondary cleavage sites, respectively. Left panel, profurin; middle panel, mature furin,
right panel, close-up. Bottom panels – In the K117P mutant the formation of an additional helix is necessary to eject the emerging N-terminus from
the active site but it is sterically forbidden because of the adjacent Pro116. As a result, the N-end region of the mature mutant enzyme continue to
occupy the S9 sub-sites leading to the inactive enzyme. The arrow 1 indicates the cleavage at the primary cleavage site alone that, as a result,
generates the liberated intact prodomain (green). Left panel, profurin; middle panel, mature furin, right panel, close-up.
doi:10.1371/journal.pone.0005031.g001
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the K117P mutant. To the contrary, the efficiency of the release of
the C-terminal peptides including G
498DLAIHLVSPMGTR
512,
the peptide from the central part of the furin sequence
(M
226LDGEVTDAVEAR
238) and many addition tryptic peptides
were highly similar in the WT and K117P furins (Figure 5). The
data summarized in Table S1 confirm our conclusion that the N-
terminal sequence of the emerging furin enzyme continues to
occupy the catalytic cleft. As a result, this N-end sequence is
protected from tryptic proteolysis, especially when compared to
WT furin in which this N-terminal region is exposed and,
therefore, can be easily accessed by trypsin.
The residual levels of the inhibitory prodomain are
associated with mutant furins
To exclude the possibility that the low proteolytic activity was
due to the presence of the residual levels of the inhibitory
prodomain in the furin samples, we evaluated the WT and K117P,
G5 and G6 purified samples by Western blotting with the MON-
150 antibody against the prodomain (Figure 6A). The WT samples
did not show the presence of the prodomain. The purified mutants
contained the residual levels of the 10 kDa prodomain. The
molecular mass of the prodomain correlated with its full-length
27–107 sequence indicating that while the primary Arg-Thr-Lys-
Arg
107QAsp
108 cleavage site was autocatalytically processed the
secondary cleavage site (Arg-Gly-Val-Thr-Lys-Arg
75QSer
76) re-
mained intact in the mutants.
An additional analysis of the fractions eluted from the metal-
chelating column in the course of the purification of the K117P
mutant demonstrated that the prodomain was co-purified with the
mature mutant enzyme (Figure 6B). The prodomain contamina-
tion, however, was successfully removed from the samples when
the metal-chelating chromatography was performed in the
presence of 1 M NaCl. We also demonstrated that the prodomain
contamination did not affect the cleavage activity of the K117P
mutant. Indeed, the activity of the K117P mutant samples which
did and did not contain the prodomain remained similarly low
(Figure 6C).
To verify that the mutant furins exhibited the full-length 27–107
prodomain, we co-incubated the G6-furin sample with the purified
WT furin. The reactions were analyzed by Western blotting with
the MON-150 antibody against the prodomain. As expected, the
WT furin readily cleaved the secondary cleavage site (Arg-Gly-
Val-Thr-Lys-Arg
75QSer
76) in the prodomain of the G6 sample
and inactivated its immunoreactivity (Figure 6D).
Prodomain cleavage in trans
To gain additional insight into the proteolytic pathway that
prevents re-inhibition of furin by the residual amount of its
inhibitory prodomain (Figure 7A), we re-examined proteolysis of
the prodomain sequence by furin. For this purpose, we subjected
the purified individual prodomain sequence to furin proteolysis in
trans (Figure 7B). Because the prodomain construct was expressed
in frame with a His6 tag sequence and a short Xpress tag, the
sequence of the actual prodomain commenced from Gln27
Figure 2. Constructs and the purification of soluble furin. (A)
Furin constructs. The constructs were truncated at position Ala574 and
C-terminally linked to a Gly3-Ser-Gly3 linker followed by a His6 tag. To
generate insertion mutants, the Gly (G), Gly-Gly-Gly-Gly-Gly (G5), Gly-
Gly-Gly-Gly-Gly-Gly (G6), Asp-Asp-Asp-Asp-Lys (D4K) and His-His-His-
His-His-His (H6) sequences (enlarged) were inserted between positions
Pro113 and Thr114 of the furin sequence. The hinge motion Lys117 and
the essential Asp153 were mutated to generate the K117P and inert
D153N constructs. SP, PRO, CAT, P, Cys-rich, TM and CT, signal peptide,
prodomain, catalytic domain, P domain, cysteine-rich region, trans-
membrane domain anchor and cytoplasmic tail, respectively. The
primary Arg-Thr-Lys-Arg
107QAsp
108 autocatalytic cleavage site is shown
by an arrow. The numbers show the molecular mass of the furin
constructs. (B) Intracellular and secreted furin in Sf9 cells. Cells (2610
6/
ml) were placed in wells of a 6-well plate and infected with the
respective recombinant baculoviruses with a 1–2 multiplicity of
infection. After a 36–38 h incubation at 27uC the cells and the 1 ml
medium samples were collected. Cells were then lysed in 1 ml 50 mM
Tris-HCl, pH 8.0, containing 1% SDS, 1 mM EDTA, 100 mM NaCl, 1 mM
phenylmethyl sulfonylfluoride and protease inhibitor cocktail. Both the
cell lysate and medium samples (1 ml each) were analyzed by Western
blotting with the MON-148 antibody against the catalytic domain of
furin. C, Purification of furin by metal-chelating chromatography. Upper
panel - Impurities were removed using a linear gradient of 0–25 mM
imidazole; furin was eluted with 500 mM imidazole. In the chromato-
gram, the furin-containing fractions are marked with a solid line. Inset -
SDS-PAGE of the 500 mM imidazole fraction. Lower panel - SDS-PAGE (1
mg protein/lane) followed by Coomassie staining (CS) and Western
blotting (WB; 100 ng protein/lane) of the purified furin samples.
doi:10.1371/journal.pone.0005031.g002
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cleavage of the 13 kDa tagged prodomain at the Arg-Gly-Val-
Thr-Lys-Arg
75QSer
76 that should result in two peptide products
[18,19,21], furin proteolysis of the prodomain followed by SDS-
PAGE demonstrated the existence of two cleavage sites and the
presence of three distinct products with apparent molecular
weights of ,10 kDa, ,5 kDa and ,3 kDa in the cleavage
reactions. Dec-RVKR-cmk reversed the effect of furin and rescued
the prodomain from furin proteolysis. N-terminal sequencing
determined that the 5 kDa fragment commenced from Ser76 and
therefore represented the 76–107 region of the prodomain. The
determined N-terminal sequence (EPQVQ) suggested that the 3
kDa fragment represented the 90–107 C-terminal sequence of the
prodomain (Figure 7C).
Proteolytic processing of the prodomain in LoVo cells
confirms a three-step mechanism
To confirm the importance of the cleavage at the tertiary
cleavage site (Arg-Leu-Gln-Arg
89QGlu
90) in the autocatalytic
processing of profurin, we prepared the full-length WT furin and
also the constructs in which the primary (R107G), the secondary
(K74G/R75G) and the tertiary (R89G) cleavage sites were each
inactivated by mutations. We also constructed the double (R89G/
R107G, K74G/R75G/R89G and K74G/R75G/R107G) and the
Figure 4. Binding of mutant furins with a1-PDX. (A) Stable complex formation between a1-PDX and furin. a1-PDX (5 mg) and furins (500 ng
each) were co-incubated for 15 min. The reactions were stopped by 5 mM EDTA and 2% SDS, heated for 3 min at 95uC and then a 1/10 part of each
reaction was analyzed by Western blotting with the MON-148 antibody against the catalytic domain of furin (upper panel) and a 9/10 part was used
in SDS-PAGE followed by Coomassie staining (lower panel). Note the presence of the kinetically trapped, SDS-resistant a1-PDX complex with the WT
furin. (B) ELISA of non-covalent complexes between a1-PDX and furins. The wells of a 96-well plate were coated with purified furins. FLAG-tagged al-
PDX was allowed to bind immobilized furins. The levels of the resulting complex were determined using a FLAG antibody followed by peroxidase-
conjugated donkey anti-mouse IgG and a TMB/E substrate.
doi:10.1371/journal.pone.0005031.g004
Figure 3. Characterization of mutant furins. (A) Specific activity of mutant furins against Abz-Arg-Val-Lys-Arg-Gly-Leu-Ala-Tyr(NO2)-Asp-OH. The
substrate was efficiently cleaved by the WT furin (1 nM) while the mutants (1 mM) were ,1000-less active. (B) Cleavage of anthrax PA83 by mutant
furins. PA83 (1 mg) was co-incubated for 1 h at 37uC with the purified furin samples at the indicated enzyme-substrate ratio. The digest samples were
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and three cleavage sites, respectively, were inactivated by
mutations. In addition, we prepared the full-length inert D153N
furin. The constructs were transiently transfected in colon
carcinoma LoVo cells. We specifically selected LoVo cells for
these studies because of the two frameshift mutations in the furin
gene of these cells do not allow them to produce furin [32].
Transiently transfected cells were lysed and the lysates were
analyzed by Western blotting using the antibodies against the
catalytic domain and the cytoplasmic tail of furin (MON-148 and
MON-139, respectively). The WT furin was efficiently activated in
LoVo cells and generated the intermediate and the mature
enzyme (Figure 7D). The efficiency of self-activation of the R89G
mutant in which the tertiary cleavage site (Arg-Leu-Gln-
Arg
89QGlu
90) was inactivated, was significantly reduced com-
pared to that of WT furin. The inert mutant (D153N), the primary
(R107G) and the secondary (K74G/R75G) cleavage site mutants
as well as the double and triple mutants (K74G/R75G/R89G,
K74G/R75G/R107G, R89G/R107G, K74G/R75G/R89G/
R107G) were incapable of self-activation and, as a result, only
the profurin form was detected in the corresponding cell lysates
(Figure 7D). Based on these results, we conclude that the cleavage
at the tertiary cleavage site (Arg-Leu-Gln-Arg
89QGlu
90) and a
three-step processing is required for the efficient autocatalytic
processing and inactivation of the furin inhibitory prodomain in
vivo. We suggest that this extensive, three-step processing helps the
emerging furin to escape re-inhibition by the residual levels of the
non-covalently associated prodomain.
Discussion
To prevent unwanted protein degradation and to enable spatial
and temporal regulation of proteolytic activity, proteolytic
enzymes are synthesized as latent precursors [9,33]. Proteolytic
removal of the activation segment (which is also called the
inhibitory prodomain) is required to generate a mature, function-
ally potent, enzyme. The prodomain size ranges from short
peptide sequences to independently folded domains over 100
residues. In the multiple proteinases in which the preformed active
site exists in the latent precursor, the prodomain sterically blocks
the active site, and thereby prevents binding of substrates. In
addition to their inhibitory role, the prodomain regions are
frequently important for the folding, stability, and intracellular
sorting of the latent precursor. Conversion to an active enzyme is
stimulated by a change in pH that results in conversion by an
autocatalytic mechanism. The requirement of the autocatalytic
mechanism is well established for furin, the ubiquitous proprotein
convertase that plays a highly significant role in the proteolytic
processing of numerous functionally important proteins and
peptides. Similar mechanisms are involved in the self-activation
of PCs distinct from furin. The complexity of subcellular
trafficking and the role of the associated factors (eg. heparan
sulfate proteoglycan) in the regulation of PC activation, however,
are not completely understood [34].
Generally, activation of furin requires several steps subsequent
to the initial cleavage of its inhibitory N-terminal propeptide. As a
result of these cleavages, the propeptide inhibitory activity is
Figure 6. The presence of the residual levels of the intact prodomain in the mutant furin samples. (A) Western blotting of the purified
furins. The purified furin samples (2 mg each) were analyzed by Western blotting with the MON-150 antibody against the furin prodomain. (B) The
prodomain is separated from the activated K117P furin in the course of performing metal-chelating chromatography in the presence of 1 M NaCl. The
K117P furin sample was purified by metal-chelating chromatography. The fractions eluted from the column using 500 mM imidazole were analyzed
by Western blotting with the MON-148 antibody against the catalytic domain (upper panel) and with the MON-150 antibody against the prodomain
of furin (two bottom panels). The 500 mM imidazole elution buffer did (+NaCl) or did not (-NaCl) contain 1 M NaCl. The presence of 1 mM NaCl had no
effect on the elution profile of the K117P mature furin (upper panel). (C) Specific activity of the purified WT and K117P furins against Abz-Arg-Val-Lys-
Arg-Gly-Leu-Ala-Tyr(NO2)-Asp-OH. The K117 mutant samples were purified either with or without 1 M NaCl and, therefore, the samples we tested
either did or did not contain the residual levels of the prodomain (PRO). (D) The WT furin cleaves the prodomain observed in the G6-furin sample. The
G6-furin sample (4 mg) which was purified in the absence of 1 M NaCl and therefore contained the residual amounts of the full-length prodomain, was
co-incubated for 1 h at 37uC with purified furin (0.5 mg). The reactions were analyzed by Western blotting with the MON-150 antibody against the
furin prodomain.
doi:10.1371/journal.pone.0005031.g006
Figure 5. Mass spectrometry analysis of tryptic peptides. The
K117P mutant and WT furin were subjected to a mild tryptic digest
(trypsin-furin ratio of 1:100 and 1:1000 w/w, 5 min). The digests were
analyzed by LC-MS/MS. The relative yield of the representative N-
terminal (D
108VYQEPTDPKFPQQWYLSGVTQR
130) and the C-terminal
(R
498GDLAIHLVSPMGTR
512) peptides and the peptide from the central
part of the furin sequence (M
226LDGEVTDAVEAR
238) was determined
using the differential peptide spectral count analysis. The yield of the
WT peptides was taken as 100%. The data of the spectral count analysis
of the selected peptides are summarized in Table S1.
doi:10.1371/journal.pone.0005031.g005
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from the active site of the emerging active furin enzyme
[2,14,15,16,17,18,19,21]. Earlier studies of the furin activation
pathway have primarily been focused on processing the N-
terminal prodomain thus leaving the structural re-arrangements of
the N-terminal region of the emerging enzyme incompletely
understood [7,19,21,35]. Because the atomic resolution structures
of the catalytic domain of furin and the prodomain of furin-like
PC1 are known [22,25,36], we modeled the interactions of the
prodomain and the catalytic domain which are characteristic for
Figure 7. Furin proteolysis in trans of its inhibitory prodomain. (A) The recombinant furin prodomain was cloned into the pTrcHis A vector
and expressed in E. coli. The sequence of the furin prodomain Gln27-Arg107 is in bold. The cleavage sites are indicated by the arrows. The N-terminal
peptide sequence of the prodomain starts from Gly2 because of the cleavage of the initiating Met1 in E. coli. The sequence of the cleavage products
determined by N-terminal sequencing is underlined. The sequence of the Xpress tag and His6 tag is italicized. The numbering used is for intact
translated human furin. (B) The recombinant furin prodomain (1.8 mg) was incubated at 37uC for 1 h with furin at a molar ratio of 1:1 or 2:1. The digest
samples were analyzed by Tricine gel electrophoresis followed by Coomassie staining. Where indicated, dec-RVKR-cmk (50 mM) was added. The
sequence numbering of prodomain and cleavage products identified by MS analysis is shown on the left side. (C) The molecular mass of the intact
recombinant furin prodomain and the cleavage products was determined by MALDI-TOF MS. The calculated and measured molecular mass of the
peptides is shown in Da. (D) A Western blotting analysis of colon carcinoma LoVo cells transiently transfected with the WT furin (WT), the catalytically
inert D153N mutant (D153N) and the furin mutants in which the primary (R107G), the secondary (K74G/R75G) and the tertiary (R89G) cleavage sites
were inactivated in the prodomain sequence. The R89G/R107G; K74G/R75G/R89G and K74G/R75G/R107G, and K74G/R75G/R89G/R107G are the
mutants in which two and three cleavage sites, respectively, were inactivated by mutations. Mock cells are LoVo cells transfected with the original
plasmid. The antibodies to the catalytic domain and to the cytoplasmic tail of furin (MON-148 and MON-139, respectively) were used for Western
blotting. To show equal loading, the samples were also analyzed by Western blotting with an a-tubulin antibody (bottom panel).
doi:10.1371/journal.pone.0005031.g007
Activation of Furin
PLoS ONE | www.plosone.org 8 April 2009 | Volume 4 | Issue 4 | e5031profurin and the transitions of the structure that follow the
autocatalytic processing at the primary Arg-Thr-Lys-Arg
107-
QAsp
108 site. It appears from our in silico modeling that the
relative position of the N-terminal region of the catalytic domain is
distinct in profurin and in mature furin. Following the cleavage at
the primary site Arg-Thr-Lys-Arg
107QAsp
108, the N-terminal
region moves away from its original position in profurin to reach
its final position in the mature furin molecule.
According to our modeling, the electrostatic interactions of
Asp115 with the calcium ion are especially important for the re-
positioning of the N-terminal 108–113 region. The electrostatic
interactions involving Asp115 and the calcium ion perform like a
‘‘loaded spring’’ and this spring is released after the pro-region
cleavage to facilitate re-positioning of the N-terminal region from
its original position in the furin zymogen to its final position in the
mature, processed, furin. Our modeling also suggested that the
peptide insertions provide an opportunity for the N-terminal part
of the emerging furin to remain largely immobile after the
autocatalytic cleavage at Arg-Thr-Lys-Arg
107QAsp
108 and to
continue to occupy the active site cavity in the mutants. As a
result, the release mechanism remained inactivated and, we
suspect, the mutants remained self-inhibited by the mature furin
N-end region which continued to occupy the S9 positions of the
catalytic cleft (Figure 8A).
To investigate these suspicions and to elucidate the auto-
inhibitory function of the N-terminal region in greater detail, we
studied the profurin mutants with the K117P mutation of the
hinge motion Lys117 and the one, five and six residue insertions
between positions Pro113 and Thr114. We determined that
similar to the WT furin, these mutant furins were autocatalytically
processed at the primary Arg-Thr-Lys-Arg
107QAsp
108 site yield-
ing the mature enzyme commencing from the N-terminal Asp108.
In contrast to the WT construct the purified mutants, however,
have low specific activity against the fluorescent peptide substrate
and anthrax PA83, one of the most sensitive furin substrates. Our
additional in-solution and ELISA binding assays confirmed that
although the mutants, in contrast to normal furin, were incapable
of forming an SDS- and heat stable complex with the a1-PDX
serpin, they did bind the serpin non-covalently.
Tryptic digest of WT and mutant furins followed by LC-MS/
MS and the differential peptide spectral count analysis of the
tryptic fragments confirmed our suggestion that in the K117P
mutant the N-terminal region of the emerging furin enzyme
continued to be buried in the furin’s catalytic cleft. As a result, this
N-terminal sequence of the mutant was inaccessible to trypsin,
especially when compared to WT furin.
Our in vitro cleavage and cell-based studies also identified an
autocatalytic cleavage of the prodomain at Arg-Leu-Gln-
Arg
89QGlu
90 that is in addition to the primary (Arg-Thr-Lys-
Arg
107QAsp
108) and secondary (Arg-Gly-Val-Thr-Lys-
Arg
75QSer
76) sites. Based on our results, we now believe that a
three-step processing of the auto-inhibitory prodomain is required
for its inactivation and for preventing re-inhibition of the emerging
furin enzyme by the residual amounts of the non-covalently
associated inhibitory prodomain. These results add another level
of complexity to the molecular mechanics that are involved in the
stepwise autocatalytic processing of the prodomain and imply a
role for the auxiliary proteins and associated factors in these
mechanisms [34].
Collectively, our results describe the events leading to the
activation of furin and shed additional light on the restrictive role
which is played by the enzyme’s N-terminal region in the




Reagents were purchased from Sigma-Aldrich unless indicated
otherwise. The fluorescent substrate pyroglutamic acid-Arg-Thr-
Lys-Arg-methyl-coumaryl-7-amide was obtained from Peptides
International. The internally quenched fluorogenic peptide
substrate Abz-Arg-Val-Lys-Arg-Gly-Leu-Ala-Tyr(NO2)-Asp-OH
and the furin inhibitor dec-RVKR-cmk were from Bachem.
Anthrax protective antigen-83 (PA83) was purchased from List
Biological Laboratories. FLAG-tagged furin inhibitor a1-anti-
trypsin variant Portland (a1-PDX) was from Affinity BioReagents.
Restriction enzymes were from New England Biolabs. Sf9 insect
cell line (an ovarian cell line from fall armyworm Spodoptera
frugiperda), Cellfectin Reagent and a pcDNA 3.1 Directional
TOPO Expression Kit were obtained from Invitrogen. The
baculovirus transfer vector pAcGP67-A and the BaculoGold
Linearized DNA were from BD Biosciences-Pharmingen. The
Fugene HD transfection reagent was from Roche Diagnostics. Sf9
insect cells were routinely grown in Sf-900 II SFM medium
supplemented with penicillin-streptomycin (100 units/ml and 100
mg/ml, respectively) and Fungizone/amphotericin B (0.25 mg/ml;
Omega). The murine MON-148, MON-150 and MON-139
monoclonal antibodies against the catalytic domain, the prodo-
main and the cytoplasmic tail of furin, respectively, were from
Axxora. The rabbit a-tubulin antibody was from Cell Signaling
Technology. The peroxidase-conjugated donkey anti-mouse and
anti-rabbit IgG were from Jackson ImmunoResearch Laborato-
ries. The TMB/M and TMB/E substrates were purchased from
Chemicon.
Cloning of human furin and plasmid construction for the
baculovirus expression system
Furin was amplified by PCR from a Marathon-Ready cDNA
library (Clontech) with the 59-ATGGAGCTGAGGCCCTGGT-
Figure 8. Self-activation of proproteinases requires the relo-
cation of the N-terminus. Schematic representation of the autolytic
activation mechanism of profurin. The 1 and 2 arrows above the protein
sequence indicate the primary and secondary cleavage sites. The N-
terminal Asp108 is shown in red. The mutant positions are underlined.
The mutants do not perform the secondary cleavage and as a result the
full-length prodomain sequence is liberated. This is in contrast to the
WT processing which involves both the primary and the secondary
cleavages of the prodomain and, as a result, two short fragments are
generated. The repositioning of N-terminus is inactivated in the K117P
and the G6 mutants.
doi:10.1371/journal.pone.0005031.g008
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nucleotides as direct and reverse primers, respectively. The
resulting 2.4 kb cDNA fragment was cloned into the HincII site
of the pUC18 plasmid and then recloned into the pcDNA3-zeo
plasmid pre-digested with HindIII and EcoRI. The furin cDNA was
then used as a template for preparing the furin constructs. Soluble
furin was truncated at the position Ala574 (numbering starts from
the initiation Met-1 of pre-profurin) and then C-terminally tagged
with a Gly3-Ser-Gly3 linker followed by a His6 tag. The 59-
TGATAGCCCGGGCAGGGCCAGAAGGTCTTCACCAAC-
ACGTGGGCTGTGCGCATC-39 and the 59-AGGTATACA-
CGCGGCCGCTTAATGGTGATGATGATGGTGACCTCCC-
CCAGAACCTCCCCCGGCGGTGCCATAGAGTACGAG-39 ol-
igonucleotides were used as direct and reverse primers,
respectively, in the PCR reactions (the His6 tag sequence is
underlined and the linker sequence is italicized).
In the primers shown below the mutant positions are
underlined. The K117P mutant (furin K117P) was generated by
PCR mutagenesis using the 59-TACCAGGAGCCCACAGA-
CCCCCCGTTTCCTCAGCAGTGGTACCTG-39 and 59-CA-
GGTACCACTGCTGAGGAAACGGGGGGTCTGTGGGCT-
CCTGGTA-39 forward and reverse primers, respectively. The
D153N catalytically inert furin (furin D153N) with the substitution
of the essential active site Asp153 was generated using the 59-
GGCATTGTGGTCTCCATTCTGAACGATGGCATCGAG-
AAGAACCAC-39 and 59-GTGGTTCTTCTCGATGCCATC-
GTTCAGAATGGAGACCACAATGCC-39 forward and reverse
primers, respectively.
To construct the insertion mutants, the Gly (G), Gly-Gly-Gly-
Gly-Gly (G5), Gly-Gly-Gly-Gly-Gly-Gly (G6), His-His-His-His-
His-His (H6) and Asp-Asp-Asp-Asp-Lys (D4K) sequences were
each inserted by PCR mutagenesis between the positions Pro113
and Thr114 of the furin sequence. The G mutant (G-furin) was
constructed using the 59-GGGACGTGTACCAGGAGCCCGG-
CACAGACCCCAAGTTTCCTCA-39 and 59-TGAGGAAACT-
TGGGGTCTGTGCCGGGCTCCTGGTACACGTCCC-39 ol-
igonucleotides as the forward and reverse primers, respectively.
The 59-GGGACGTGTACCAGGAGCCCGGCGGTGGCGG-
TGGCACAGACCCCAAGTTTCCTCA-39 (forward) and the
59-TGAGGAAACTTGGGGTCTGTGCCACCGCCACCGC-
CGGGCTCCTGGTACACGTCCC-39 (reverse) primers were
used to obtain the G5 mutant (G5-furin). The 59-GGGACGTG-
TACCAGGAGCCCGGTGGCGGTGGCGGTGGCACAGA-
CCCCAAGTTTCCTCA-39 (direct) and the 59-TGAGGAAAC-
TTGGGGTCTGTGCCACCGCCACCGCCACCGGGCTCC-
TGGTACACGTCCC-39 (reverse) primers were used to prepare
the G6 mutant (G6-furin). The His6 mutant (H6-furin) was




as the forward and reverse primers, respectively. The 59-GG-
GACGTGTACCAGGAGCCCGACGATGACGATAAGACAG-
ACCCCAAGTTTCCTCA-39 (direct) and the 59-TGAGGA-
AACTTGGGGTCTGTCTTATCGTCATCGTCGGGCTCC-
TGGTACACGTCCC-39 (reverse) primerswereusedtoobtainthe
D4K mutant (D4K-furin). The resulting constructs were cloned into
the XmaI and NotIsitesofthepAcGP67-Avector.The authenticityof
the constructs was confirmed by DNA sequencing.
The wild-type and mutant furin constructs expressed in
colon carcinoma LoVo cells
The full-length human furin cDNA was sub-cloned into the
pcDNA 3.1/V5-His-TOPO using the 59-CACCATGGAGCT-
GAGGCCCTGGTTGCTATGGGTGGTAGCAGCAACAG-
GAACCTT-39 and the 59-TCAGAGGGCGCTCTGGTCTTT-
39 oligonucleotides as forward and reverse primers, respectively.






76) and tertiary (Arg-Leu-Gln-Arg
89QGlu
90) autocata-
lytic cleavage sites were generated by PCR mutagenesis using the
wild-type furin template. The forward 59-GTGGCAAAGC-
GACGGACTAAAGGGGACGTGTACCAGGAGCCCACA-39
and reverse 59-TGTGGGCTCCTGGTACACGTCCCCTT-
TAGTCCGTCGCTTTGCCAC-39 primers were used to con-
struct the primary cleavage site mutant (R107G). The forward 59-
TGGCATCGAGGAGTGACGGGGGGGTCCCTGTCGCCT-
CACCGC-39 and the reverse 59-GCGGTGAGGCGACAGG-
GACCCCCCCGTCACTCCTCGATGCCA-39 primers were
used to construct the secondary cleavage site mutant (K74G/
R75G). The forward 59-CGGCACAGCCGGCTGCAGGGGG-
AGCCTCAAGTACAGTGG-39 and the reverse 59-CCACTGT-
ACTTGAGGCTCCCCCTGCAGCCGGCTGTGCCG-39 prim-
ers were used to construct the tertiary cleavage site mutant
(R89G). The double and triple mutants (K74G/R75G/R89G;
K74G/R75G/R107G; R89G/R107G; K74G/R75G/R89G/
R107G) in which two and three cleavage sites were inactivated
by mutations were obtained by routine genetic engineering
manipulations. The full-length D153N catalytically inert furin
with the substitution of the essential active site Asp153 was
generated using the 59-GGCATTGTGGTCTCCATTCT-
GAACGATGGCATCGAGAAGAACCAC-39 and 59-GTGGT-
TCTTCTCGATGCCATCGTTCAGAATGGAGACCACAAT-
GCC-39 forward and reverse primers, respectively. The furin
mutant constructs were cloned into the pcDNA 3.1/V5-His-
TOPO and their sequences were confirmed by DNA sequencing.
Human colon carcinoma LoVo cells (ATCC) were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum. Sub-confluent LoVo cells (5610
5)w e r e
transfected with 3 ml of Fugene HD reagent per 1 mgo fD N A .
Twenty four h after tranfection, cells were lysed in 50 mM
Tris-HCl pH 8.0, supplemented with 1% SDS, 1 mM EDTA,
100 mM NaCl, 1 mM phenylmethyl sulfonylfluoride, and a
protease inhibitor cocktail. The lysate samples (5 mgt o t a l
p r o t e i ne a c h )w e r ea n a l y z e db yW e s t e r nb l o t t i n gw i t ht h ef u r i n
antibodies.
Furin expression and purification
Sf9 cells were co-transfected with the recombinant pAcGP67-
A vectors and the BaculoGold linearized DNA using Cellfectin.
The amplification of the recombinant baculovirus and the
preparation of a high-titer viral stock were performed in Sf9 cells
according to the manufacturer’s instructions (Invitrogen). Cells
(2610
6 cell/ml) infected at a multiplicity of infection 1–2 were
then cultured in suspension at 27uC in Sf-900 II SFM medium (1
L). After a 36–38 h incubation, the medium was centrifuged at
2006g and then at 15,0006g (30 min each; 4uC). The
supernatant was concentrated 20-fold using an Amicon Ultra
30K-cutoff membrane (Millipore). 1 M Tris-HCl, pH 8.0, was
added to the samples to obtain a final concentration of 20 mM.
Furin was isolated from the medium samples using Ni
2+-
chelating chromatography on the HiTrap Chelating HP
1.662.5 cm size column (Amersham Biosciences) equilibrated
with PBS. After eluting the impurities with 60 ml of a linear
gradient of 0–25 mM imidazole, furin was eluted with 500 mM
imidazole. Where indicated, 1 M NaCl was included in all of the
buffers used for the purification of furin. The purified fractions
were pooled, dialyzed against PBS and stored at -80uC. Purified
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and enzyme activity assays. The typical yield of purified furin
was approximately 1 mg/liter of cell culture medium. Following
SDS-PAGE and the transfer of the proteins onto a membrane
support, the N-terminal peptide sequence of furin was deter-
mined by N-terminal microsequencing at ProSeq (Boxford, MA).
The SDS- and heat-stable complexes of furin with a1-PDX
For the SDS-gel analysis followed by Coomassie staining, a1-
PDX (5 mg, 10 mM) was co-incubated for 15 min at ambient
temperature with furin (0.5 mg, 1 mM) in either PBS or the Sf-900
II SFM medium. For the Western blot analysis, the concentrations
of a1-PDX and furin in the reactions were 10-fold less (0.5 mg and
50 ng, respectively). Furin activity was blocked by adding 5 mM
EDTA and the 26SDS-PAGE sample buffer (125 mM Tris-HCl,
pH 6.8, 4% SDS, 0.005% Bromophenol Blue, 20 mM DTT and
20% glycerol) to the reactions. The reactions were heated for 3
min at 95uC and then analyzed by SDS-PAGE in a 4–20%
acrylamide gradient gel followed by either Coomassie staining or
Western blotting of the reaction aliquots with the MON-148
antibody.
ELISA of the furin-a1-PDX complexes
To measure the efficiency of the a1-PDX binding with furin,
the wells of a 96-well plate (Nunc) were coated for 16 h at 4uC
with purified furin constructs (1 mg/ml in 100 ml PBS). BSA (1
mg/ml 100 ml PBS) was used as a control. The wells were then
blocked with 3% BSA in PBS-0.05% Tween 20 for 2 h at the
ambient temperature. a1-PDX (50 mg/ml in 100 mlP B S
containing 3% BSA and 0.05% Tween 20) was added to the
wells and the plates were incubated for 1 h at the ambient
temperature. After washing the wells five times with PBS-0.05%
T w e e n2 0 ,t h em u r i n eF L A GM 2a n t i b o d y( 0 . 5mg/ml in 100 ml
PBS containing 3% BSA and 0.05% Tween 20) was added to the
wells and the plates were incubated 1 h at the ambient
temperature. The unbound antibody was removed by washings
with PBS-0.05% Tween 20. The peroxidase-conjugated donkey
anti-mouse IgG (1:10,000 dilution) was added to the wells for 1
h. Following extensive washing with PBS-0.05% Tween 20 and
then with water, a TMB/E substrate was added to the wells. The
reaction was stopped by adding 0.1 ml 1 M H2SO4.T h eA 450
value was measured using a plate reader. The samples were
analyzed in triplicate.
Purification of the furin prodomain
The prodomain was prepared using PCR amplification of the
full-length furin cDNA. The 59-CAGAAGGTCTTCACCAA-
CACG-39 and 59-TCACCGTTTAGTCCGTCGCTTTGC-39
oligonucleotides were used as direct and reverse primers,
respectively, in the PCR reactions. The amplified fragment
contained the prodomain sequence from Gln27 to the Arg-Thr-
Lys-Arg
107Q primary cleavage site. The PCR fragment was
subcloned into the pTrcHis A vector (Invitrogen). The resulting
protein was expressed in frame with a His6 tag sequence, a linker
region and an additional Xpress short tag. One Shot TOP 10
E.coli cells (Invitrogen) were transformed with the recombinant
prodomain construct. The expression of the recombinant protein
was induced with 1 mM isopropyl-1-thio-b-D-galactopyranoside.
The collected cells were lysed, and the recombinant prodomain
was purified from the cell lysates using Ni
2+-chelating chromatog-
raphy and reverse-phase HPLC. The purity of the recombinant
prodomain construct was confirmed by SDS-PAGE and mass
spectrometry.
Cleavage of the furin prodomain
The furin prodomain (1.8 mg, 3.4 mM) was co-incubated with
the purified furin samples (an enzyme-substrate ratio of 1:1 and
1:2) for 1 h at 37uC in 100 mM Hepes, pH 7.5, containing 1 mM
CaCl2 and 1 mM b-mercaptoethanol. Where indicated, dec-
RVKR-cmk (50 mM) was added to the reactions. The molecular
mass of the intact prodomain and the digest products was
determined by MALDI-TOF mass spectrometry on a Brucker
Daltonics Autoflex II TOF/TOF mass spectrometer. To deter-
mine the N-terminal peptide sequence of the cleavage products
and, consequently, the scissile bond, the reactions were separated
by Tricine/SDS-PAGE in a 10–20% polyacrylamide gradient gel
followed by the transfer of the digest fragments onto a membrane
support. The Coomassie stained bands were excised and their N-
terminal sequence was determined by N-terminal microsequen-
cing at ProSeq.
Tryptic proteolysis of furin and mass spectrometry
The purified WT and K117P furins (0.4 mg/ml each) were co-
incubated for 5 min at 37uC in with trypsin (Promega) at a trypsin-
furin ratio of 1:100 and 1:1000 (w/w) in PBS. Trypsin was then
inactivated by 1 mM phenylmethyl sulfonylfluoride. The digest
peptides were analyzed by LC-MS/MS using an Eksigent Nano
2D-LC system coupled with LTQ mass spectrometer (Thermo
Scientific). The spectra were searched using Sorcerer SEQUEST
(Sage-N Research) and filtered by PeptideProphet (Institute for
Systems Biology; http://peptideprophet.sourceforge.net). Only
the peptides with a probability score that exceeded 0.95 and a
cross-correlation (Xcorr) value that exceeded 2.0 were further
considered. The yield of the tryptic peptides was measured using
the differential peptide spectral count analysis [37,38].
Enzymatic assays
Furin activity was measured in wells of a 96 well plate in 0.2 ml
100 mM Hepes, pH 7.5, containing 1 mM CaCl2,1m Mb-
mercaptoethanol and 0.005% Brij35. Abz-Arg-Val-Lys-Arg-Gly-
Leu-Ala-Tyr(NO2)-Asp-OH (5 mM) was used as a substrate. The
concentration of the wild-type (WT) and mutant furin in the
reactions was 1 nM and 1 mM, respectively. The steady-state rate
of substrate hydrolysis was monitored continuously (lex=320 nm
and lem=420 nm) at 37uC using a fluorescence spectrophotom-
eter. When the Pyr-Arg-Thr-Lys-Arg-methyl-coumaryl-7-amide
substrate was used, the steady-state rate was monitored at
lex=360 nm and lem=465 nm. The samples were measured in
triplicate.
Furin proteolysis of anthrax PA83
PA83 (1 mg, 1.2 mM) was co-incubated with furin at the
indicated enzyme-substrate ratio for 1 h at 37uC in 100 mM
Hepes, pH 7.5, containing 1 mM CaCl2 and 1 mM b-
mercaptoethanol. The reactions were stopped by adding 26
SDS-PAGE sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS,
0.005% Bromophenol Blue, 20 mM DTT and 20% glycerol) to
the samples. The digest reactions were analyzed in an 8–16%
polyacrylamide gradient gel.
Structure modeling
The structure of the human WT and mutant profurin was
modeled using the available coordinates of the highly homologous
(97% identity) catalytic domain and P-domain of murine 108–574
furin (Protein Data Bank code 1P8J) and the prodomain of murine
26–107 PC1 (37% identity; Protein Data Bank code 1KN6) as
templates, and the Modeler software (http://ffas.ljcrf.edu). The
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the mouse furin catalytic domain using the DOT program (www.
sdcs.edu/CCMS/DOT). To avoid steric clashes the several side
chain positions were corrected manually using the Xfit program
(www.sdcs.edu/CCMS/Packages/XTALVIEW/xtalview.html).
The structure was then energy-minimized using the CHARMm22
force field molecular dynamics software of the Discovery Studio
software package (Accelrys, http://www.accelrys.com/products/




Found at: doi:10.1371/journal.pone.0005031.s001 (0.05 MB
DOC)
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